Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - mycoplasma synoviae strain ms-h vaccine, living - misc. aural, ophthalmic, oro/naso pharyngeal - mycoplasma synoviae strain ms-h vaccine, living vaccine-general active 105.7 ccu/dose - immunotherapy - poultry broilers (meat for human consum) | poultry layers (eggs for human consump) | poultry pullets (growing chook) | breeding - airsacculitis | chronic respiratory disease | infectious synovitis | vaccine | equine rotavirus | ms

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - selenium as sodium selenate; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; corynebacterium pseudotuberculosis - toxoid - misc. vaccines or anti sera - selenium as sodium selenate mineral-selenium active 0.5 g/l; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; clostridium tetani - toxoid vaccine-toxoid active 0.0 p; corynebacterium pseudotuberculosis - toxoid vaccine-toxoid active 0.0 p - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - black disease | blackleg | cheesy gland | enterotoxaemia (pulpy kidney) | malignant oedema | selenium deficiency | tetanus | clostridium perfringens type d | lymphadenitis | lymphangitis | tetanus vaccination | white muscle disease

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis a vaccine 50 u/ml - suspension for injection - 50 u/ml - active: hepatitis a vaccine 50 u/ml excipient: aluminium as amorphous aluminium hydroxyphosphate sulphate borax sodium chloride water for injection - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus. primary immunisation should be given at least 2 weeks prior to expected exposure to hav. vaccination is recommended in children 12 months of age and older, adolescents, and adults who are at risk of contracting or spreading infection or who are at risk of life-threatening disease if infected, including but not limited to: · travellers to endemic or outbreak areas · frequently affected communities - members residing in any community with one or more recorded outbreaks within the last five years · daycare - children and staff of daycare centres as well as their parents, siblings, and other contacts · military personnel prior to departure for endemic or outbreak areas · persons for whom hepatitis a is an occupational hazard - health-care workers - staff and residents of orphanages, chronic care hospitals and mental health care facilities - sewage workers · haemophiliacs and other recipients of therapeutic blood products · persons who test positive for hepatitis c virus and have diagnosed liver disease · food handlers · consumers of high-risk foods e.g. raw shellfish · persons at increased risk of the disease due to their sexual practices - homosexually-active males - persons who repeatedly contract sexually transmitted diseases · human immunodeficiency virus (hiv)-infected adults · users of illicit injectable drugs vaqta will not prevent hepatitis caused by infectious agents other than hepatitis a virus.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

Spojené státy - angličtina - NLM (National Library of Medicine)

merck sharp & dohme corp. - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (unii: luy6p8763w) (haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen - unii:luy6p8763w) - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen 1 g in 1 g

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - tetanus toxoid, quantity: 40 iu; diphtheria toxoid, quantity: 20 iu; poliovirus, quantity: 80 dagu; pertussis fimbriae 2 + 3, quantity: 5 microgram; haemophilus influenza type b polyribose ribitol phosphate, quantity: 3 microgram; pertussis toxoid, quantity: 20 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram; hepatitis b surface antigen, quantity: 10 microgram; pertactin, quantity: 3 microgram - injection, suspension - excipient ingredients: aluminium; water for injections; dibasic sodium phosphate; monobasic sodium phosphate - vaxelis (dtpa5-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).,the use of vaxelis should be in accordance with official recommendations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - tetanus toxoid, quantity: 40 iu; diphtheria toxoid, quantity: 20 iu; poliovirus, quantity: 80 dagu; pertussis fimbriae 2 + 3, quantity: 5 microgram; haemophilus influenza type b polyribose ribitol phosphate, quantity: 3 microgram; pertussis toxoid, quantity: 20 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram; hepatitis b surface antigen, quantity: 10 microgram; pertactin, quantity: 3 microgram - injection, suspension - excipient ingredients: aluminium; water for injections; dibasic sodium phosphate; monobasic sodium phosphate - vaxelis (dtpa5-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).,the use of vaxelis should be in accordance with official recommendations.

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - streptococcus equi; thiomersal - misc. vaccines or anti sera - streptococcus equi vaccine-microbial active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - strangles | vaccine | equine rotavirus

Evropská unie - angličtina - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.

Austrálie - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - live fowl adenovirus - misc. vaccines or anti sera - live fowl adenovirus vaccine-viral active 0.0 ml - immunotherapy - poultry chicks - up to 28 days old | chicks of vaccinated hens - homologous types of fowl adenovirus infe | inclusion body hepatitus